HC Wainwright Has Bullish Estimate for RARE Q3 Earnings

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) – Analysts at HC Wainwright lifted their Q3 2026 earnings estimates for Ultragenyx Pharmaceutical in a research report issued to clients and investors on Monday, August 10th. HC Wainwright analyst R. Selvaraju now expects that the biopharmaceutical company will earn $0.75 per share for the quarter, up from their previous estimate of ($0.84). HC Wainwright has a “Buy” rating and a $50.00 price objective on the stock. The consensus estimate for Ultragenyx Pharmaceutical’s current full-year earnings is ($4.42) per share. HC Wainwright also issued estimates for Ultragenyx Pharmaceutical’s Q4 2026 earnings at $0.78 EPS, FY2026 earnings at ($1.18) EPS, Q1 2027 earnings at $0.06 EPS, Q2 2027 earnings at $0.91 EPS, Q3 2027 earnings at $1.25 EPS, Q4 2027 earnings at $2.27 EPS and FY2027 earnings at $4.50 EPS.

Other equities analysts also recently issued research reports about the company. Weiss Ratings upgraded Ultragenyx Pharmaceutical from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, July 9th. Cantor Fitzgerald increased their price objective on Ultragenyx Pharmaceutical from $84.00 to $96.00 and gave the stock an “overweight” rating in a research note on Thursday, May 21st. Royal Bank Of Canada raised their target price on Ultragenyx Pharmaceutical from $35.00 to $40.00 and gave the company an “outperform” rating in a report on Tuesday, July 7th. Wall Street Zen raised Ultragenyx Pharmaceutical from a “sell” rating to a “hold” rating in a research report on Saturday. Finally, Guggenheim decreased their price target on Ultragenyx Pharmaceutical from $43.00 to $35.00 and set a “buy” rating for the company in a report on Tuesday, August 4th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $57.82.

Ultragenyx Pharmaceutical Price Performance

RARE opened at $26.96 on Wednesday. Ultragenyx Pharmaceutical has a fifty-two week low of $18.29 and a fifty-two week high of $39.89. The firm has a market capitalization of $2.66 billion, a PE ratio of -4.62 and a beta of 0.35. The company’s 50-day moving average is $28.07 and its 200 day moving average is $24.87.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its quarterly earnings data on Tuesday, August 4th. The biopharmaceutical company reported ($0.90) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.22) by $0.32. The firm had revenue of $214.00 million during the quarter, compared to analysts’ expectations of $183.08 million. Ultragenyx Pharmaceutical had a negative net margin of 81.79% and a negative return on equity of 1,024.42%. The business’s revenue was up 28.5% on a year-over-year basis. During the same period last year, the company earned ($1.17) earnings per share.

Insider Activity

In other Ultragenyx Pharmaceutical news, Director Shehnaaz Suliman sold 5,740 shares of the stock in a transaction dated Monday, May 18th. The shares were sold at an average price of $25.12, for a total value of $144,188.80. Following the completion of the sale, the director owned 27,951 shares in the company, valued at approximately $702,129.12. This trade represents a 17.04% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP Karah Herdman Parschauer sold 1,899 shares of Ultragenyx Pharmaceutical stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $24.62, for a total transaction of $46,753.38. Following the transaction, the executive vice president directly owned 94,462 shares in the company, valued at approximately $2,325,654.44. This represents a 1.97% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 14,292 shares of company stock valued at $351,644. 5.20% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of RARE. BlackRock Inc. purchased a new position in shares of Ultragenyx Pharmaceutical in the 2nd quarter worth about $355,746,000. Vanguard Group Inc. increased its holdings in Ultragenyx Pharmaceutical by 1.3% during the fourth quarter. Vanguard Group Inc. now owns 10,263,815 shares of the biopharmaceutical company’s stock worth $236,068,000 after buying an additional 131,087 shares during the last quarter. State Street Corp increased its holdings in Ultragenyx Pharmaceutical by 16.5% during the fourth quarter. State Street Corp now owns 4,303,046 shares of the biopharmaceutical company’s stock worth $98,970,000 after buying an additional 610,559 shares during the last quarter. Wellington Management Group LLP raised its position in Ultragenyx Pharmaceutical by 26.6% in the fourth quarter. Wellington Management Group LLP now owns 2,461,910 shares of the biopharmaceutical company’s stock worth $56,624,000 after acquiring an additional 516,781 shares during the period. Finally, Assenagon Asset Management S.A. boosted its stake in Ultragenyx Pharmaceutical by 1,030.4% in the first quarter. Assenagon Asset Management S.A. now owns 2,257,671 shares of the biopharmaceutical company’s stock valued at $47,298,000 after acquiring an additional 2,057,951 shares during the last quarter. Institutional investors own 97.67% of the company’s stock.

Key Ultragenyx Pharmaceutical News

Here are the key news stories impacting Ultragenyx Pharmaceutical this week:

• Positive Sentiment: HC Wainwright maintained a “Buy” rating and $50 price target. The target remains substantially above the reference price of $26.96, signaling that the analyst sees significant value in Ultragenyx’s rare-disease pipeline and commercial growth prospects. A broader brokerage survey places the average price target at $57.82. Brokerages Set Ultragenyx Pharmaceutical Price Target
• Positive Sentiment: HC Wainwright sharply improved its near-term earnings outlook. The firm raised its Q3 2026 EPS estimate from a loss of $0.84 to a profit of $0.75, increased Q4 2026 EPS from a loss of $0.35 to $0.78, and narrowed its FY2026 loss forecast from $4.27 to $1.18 per share. These changes suggest stronger operating performance or improved revenue timing than previously expected.
• Positive Sentiment: Ultragenyx recently delivered better-than-expected quarterly results. Revenue rose 28.5% year over year to $214 million, exceeding estimates, while the quarterly loss of $0.90 per share was narrower than the expected $1.22 loss. Continued revenue growth could support the improving earnings outlook. Ultragenyx Q2 Revenue Growth and Narrower Loss
• Neutral Sentiment: Ultragenyx and Baylor Research Institute settled a DOJOLVI generic patent lawsuit with Esjay Pharma. The settlement removes some legal uncertainty surrounding the product, but the available report does not disclose the terms, launch timing, or financial impact. DOJOLVI Generic Patent Lawsuit Settlement
• Negative Sentiment: HC Wainwright reduced multiple 2027 EPS forecasts. FY2027 EPS was cut from $5.61 to $4.50, while Q1, Q2, Q3 and Q4 2027 estimates were also lowered. Although the firm still expects a return to profitability, the revisions indicate lower anticipated earnings momentum over the longer term.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.